рак молочной железыморфология сосудов опухолифакторы прогнозаbreast cancermorphology of tumor vesselsprognostic factors1.Fitzgibbons P.L., Page D.L., Weaver D. et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124(7): 966-78. DOI: 10.1043/0003- 9985(2000)124<0966: PFIBC>2.0. CO; 2. PMID: 10888772.2.ESMO Guidelines Working Group, Kalaja V.V. Recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007; 18 Suppl 2: ii 9-11. DOI: 10.1093/annonc/mdm016. PMID: 17491064.3.Lester S.C., Bose S., Chen Y.Y. et al. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med 2009; 133(10): 1515-38. DOI: 10.1043/1543-2165-133.10.1515. PMID: 19792042.4.Folkman J. Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology 1998; 139(2): 441-2. DOI: 10.1210/endo.139.2.5858. PMID: 9449608.5.Han Z., Chen Z., Zheng R. et al. Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis. World J Surg Oncol 2015; 13: 56. DOI: 10.1186/s12957-015-0486-9. PMID: 25889325.6.Gasparini G. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit Rev Oncol Hematol 2001 Feb; 37(2): 97-114. PMID: 11166583.7.Li Y.S., Kaneko M., Amatya V.J. et al. Expression of vascular endothelial growth factor-C and its receptor in invasive micropapillary carcinoma of the breast. Pathol Int 2006; 56(5): 256-61. DOI: 10.1111/j.1440-1827.2006.01961. x. PMID: 16669874.8.Popiela T.J., Sikora J., Klimek M. et al. The analysis of CD34 antigen immunoreactivity level in invasive ductal breast cancer with respect to the presence of lymph node metastases. Neuro Endocrinol Lett 2008; 29(4): 443-6. PMID: 18766141.9.Fridman V., Humblet C., Bonjean K., Boniver J. Assessment of tumor angiogenesis in invasive breast carcinomas: absence of correlation with prognosis and pathological factors. Virchows Arch 2000; 437(6): 611-7. PMID: 11193472.10.Mohammed Z.M., McMillan D.C., Edwards J. et al. The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancer. BMC Clin Pathol 2013; 13(1): 31. DOI: 10.1186/1472-6890-13-31. PMID: 24274633.11.Sullivan C.A., Ghosh S., Ocal I.T. et al. Microvessel area using automated image analysis is reproducible and is associated with prognosis in breast cancer. Hum Pathol 2009; 40(2): 156-65. DOI: 10.1016/j.humpath.2008.07.005. PMID: 18799189.12.Fernández-Guinea O., Àlvarez-Cofino A., Eirö N. et al. Low microvascular density at the tumor center is related to the expression of metalloproteases and their inhibitors and with the occurrence of distant metastasis in breast carcinomas. Int J Clin Oncol 2013; 18(4): 629-40. DOI: 10.1007/s10147-012-0428-2. PMID: 22688161.13.Birau A., Ceausu R.A., Cimpean A.M. et al. Assessement of angiogenesis reveals blood vessel heterogeneity in lung carcinoma. Oncol Lett 2012; 4(6): 1183-6. DOI: 10.3892/ol.2012.893. PMID: 23205116.14.Fukumura D., Duda D.G., Munn L.L. et al. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 2010; 17(3): 206-25. DOI: 10.1111/j.1549-8719.2010.00029.x. PMID: 20374484.15.Mikalsen L.T., Dhakal H.P., Bruland O.S. et al. The clinical impact of mean vessel size and solidity in breast carcinoma patients. PLoS One 2013;11; 8(10):e75954. DOI: 10.1371/journal.pone. 0075954. PMID: 24146798.16.Nagy J.A., Dvorak H.F. Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets. Clin Exp Metastasis 2012;29(7):657-62. DOI: 10.1007/s10585-012-9500-6. PMID: 22692562.17.Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 19913;324(1): 1-8. DOI: 10.1056/NEJM199101033240101. PMID: 1701519.18.Baluk P., Hashizume H., McDonald D.M. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005;15(1):102-11. DOI: 10.1016/j.gde.2004.12.005. PMID: 15661540.19.Luukkaa H., Laitakari J., Vahlberg T. et al. Morphometric analysis using automated image analysis of CD34-positive vessels in salivary gland acinic cell carcinoma. Acta Otolaryngol 2007;127(8):869-73. DOI: 10.1080/00016480601053099. PMID: 17763000.20.Mucci L.A., Powolny A., Giovannucci E. et al. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 2009;27(33):5627-33. DOI: 10.1200/JCO.2008.20.8876. PMID: 19858401.21.Taverna G. Fractal analysis of twodimensional vascularity in primary prostate cancer and surrounding non-tumoral parenchyma. Pathol Res Pract. 2009;205(7):438-44. DOI: 10.1016/j.prp.2008.12.019. PMID: 19232838.22.Naik R.P., Jin D., Chuang E. et al. Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res Treat 2008;107(1):133-8. DOI: 10.1007/s10549-007-9519-6. PMID: 18043899.23.Richter-Ehrenstein C., Rentzsch J., Runkel S. et al. Endothelial progenitor cells in breast cancer patients. Breast Cancer Res Treat 2007;106(3):343-9. DOI: 10.1007/s10549-007-9505-z. PMID: 17972175.24.Sussman L.K., Upalakalin J.N., Roberts M.J. et al. Blood markers for vasculogenesis increase with tumor progression in patients with breast carcinoma. Cancer Biol Ther 2003;2(3):255-6. PMID: 12878859.